WO2018226493A1 - Anticorps humain purifié se liant au motif microbien de liaison à l'héparine et son procédé d'utilisation - Google Patents

Anticorps humain purifié se liant au motif microbien de liaison à l'héparine et son procédé d'utilisation Download PDF

Info

Publication number
WO2018226493A1
WO2018226493A1 PCT/US2018/035278 US2018035278W WO2018226493A1 WO 2018226493 A1 WO2018226493 A1 WO 2018226493A1 US 2018035278 W US2018035278 W US 2018035278W WO 2018226493 A1 WO2018226493 A1 WO 2018226493A1
Authority
WO
WIPO (PCT)
Prior art keywords
human antibody
antibody
composition
stationary phase
peptide
Prior art date
Application number
PCT/US2018/035278
Other languages
English (en)
Inventor
Margaret K. Hostetter
Original Assignee
Children's Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital Medical Center filed Critical Children's Hospital Medical Center
Publication of WO2018226493A1 publication Critical patent/WO2018226493A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1218—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Acinetobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Definitions

  • a human antibody to peptide HKQEKQKKHQIHKV obtained, in one embodiment, by purifying the human antibody from a commercially available human antibody composition, such as GAMMAGARD®.
  • the antibody is used to bind to and block heparin binding domains on the surfaces of various microbes, preventing the microbes from forming biofilms on indwelling medical devices.
  • FIG. 1 shows titration data from enzyme-linked immunosorbent assay (ELISA), demonstrating high binding of the affinity purified human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1).
  • FIG. 2 shows flow cytometry results, with data obtained using the affinity purified human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1).
  • FIG. 3 shows flow cytometry results, with data obtained using the affinity purified rabbit antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1).
  • FIG. 4 schematically illustrates the portions on an immunoglobulin G (IgG) antibody.
  • IgG immunoglobulin G
  • One embodiment of the invention is a human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1) obtained by purifying the human antibody from a commercially available human immunoglobulin composition, resulting in the purified human antibody.
  • the invention is a human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1) obtained by purifying the human antibody from human plasma.
  • the commercially available human immunoglobulin composition is GAMMAGARD® (Baxalta/Shire, Baxter Healthcare, CA; cat. # NDC 0944-2700-02).
  • GAMMAGARD® Boxalta/Shire, Baxter Healthcare, CA; cat. # NDC 0944-2700-02
  • Purification and use of human antibody reactive with a 14-mer peptide encompassing a heparin binding domain of the Candida albicans protein Int1 (Accession No. C5_02470W_A; 19.4257) HKQEKQKKHQIHKV is provided.
  • an N-terminal cysteine is added to the peptide sequence to permit coupling to a support resin for affinity purification of the human antibody.
  • the titer of the affinity purified antibody reached 1 :12,500; as little as 5 ng of the peptide produced a positive response in ELISA using the described affinity purified human antibody.
  • GAMMAGARD® The qualitative and quantitative composition of GAMMAGARD® is as follows.
  • the active component is human normal IgG.
  • GAMMAGARD® is a liquid preparation of immunoglobulins, stabilized with 0.25 M glycine, without added sugars, sodium or preservatives, according to the package insert.
  • the protein concentration is 100 mg/ml (i.e. 10%), 98% of which is IgG, with about 37 ⁇ g/ml IgA and traces of IgM. It is produced from donor plasma (thousands of donors pooled) by Cohn-Oncley alcohol fractionation, ion-exchange chromatography, solvent/detergent treatment, 35 nm nanofiltration, and incubation at low pH and elevated temperature.
  • human antibody affinity purification could be performed on a more crude intermediate immunoglobulin fraction, such as prior to treatment to remove viruses (solvent/detergent inactivation, filtration, heat treatment, etc.) or unfractionated human plasma.
  • viruses solvent/detergent inactivation, filtration, heat treatment, etc.
  • unfractionated human plasma unfractionated human plasma.
  • GAMMAGARD® was employed.
  • the commercial preparation, crude intermediate immunoglobulin fraction, or unfractionated human plasma is diluted 1 :2 into PBS before affinity purification of the described human antibody.
  • the commercial preparation, crude intermediate immunoglobulin fraction, or unfractionated human plasma may be subjected to a buffer exchange column or membrane (centrifugal or pressure driven) to exchange buffer to about pH 7.4 so that the described human antibody can bind to the peptide during the affinity purification.
  • the GAMMAGARD® composition is contacted with a solid phase, also termed a stationary phase, that contains the HKQEKQKKHQIHKV (SEQ ID NO: 1) affinity ligand as the sole affinity component or ligand to which the desired antibody in the GAMMAGARD® composition will bind, bound to a support (e.g., bead, resin, etc.).
  • a support e.g., bead, resin, etc.
  • the unbound fraction also termed the flow through, lacks the desired antibody.
  • the bound antibody remains bound to the solid phase by antigen-antibody binding interactions after the washing step and is subsequently eluted or removed or collected from the solid phase.
  • the eluted antibody is then subjected to a buffer exchange procedure such as dialysis or diafiltration.
  • the eluate may also be dialyzed as a further purification step or to adjust the pH of the eluate to a physiological pH.
  • the same procedure is used with a crude intermediate immunoglobulin fraction or unfractionated human plasma.
  • One embodiment is a purified human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1), where the purification steps are contacting a composition comprising the human antibody, e.g., GAMMAGARD®, with a stationary phase that consists of a solid support and the affinity ligand HKQEKQKKHQIHKV (SEQ ID NO: 1), washing the stationary phase with a wash buffer, and eluting the human antibody from the stationary phase by contacting an elution buffer with the stationary phase.
  • a composition comprising the human antibody, e.g., GAMMAGARD®
  • a stationary phase that consists of a solid support and the affinity ligand HKQEKQKKHQIHKV (SEQ ID NO: 1)
  • One embodiment is a method to reduce or prevent biofilm on a surface of a medical device that is implanted or is indwelling, resulting in decreasing or eliminating patient infection.
  • This method addresses biofilm formation on the surface of cells or synthetic materials in medical devices.
  • Candida can form a biofilm, e.g. on the surface of a device, on epithelial/mucosal sites, or in endothelial (blood vessel) surfaces.
  • Microorganisms enmeshed in biofilms are more resistant to antibiotics, and continue to shed live organisms that may colonize other sites. The patient then mounts an exaggerated, ineffective immune response, which can lead to tissue destruction. Microbial colonization of some sites may cause an infarct at the site.
  • Microbial proteins bind heparin and heparan sulfate, which may be linked to core proteins such as syndecans or perlecan, to form heparan sulfate proteoglycans (HSPG) that are present on the surface of mammalian cells.
  • HSPG heparan sulfate proteoglycans
  • Microbes express HSPG binding proteins, also referred to as heparin binding proteins, in order to bind HSPGs.
  • Heparin binding motifs are peptide sequences that bind to both heparin and heparan sulfate, and HBM are thought to be responsible for interaction of the microbial protein with mammalian heparan sulfate proteoglycans.
  • heparin binding motif is the heparin binding sequence HKQEKQKKHQIHKV (SEQ ID NO: 1) also abbreviated as 14-mer peptide disclosed in U.S. Publication No. 2016/0257734 and U.S. Patent No. 9,409,975, each of which is expressly incorporated by reference herein in its entirety.
  • a biofilm is a multilayered structure of microbes embedded in a polysaccharide matrix that forms on medical devices, e.g., central venous catheters, implanted prosthetics, contact lenses, etc.
  • a first step in biofilm formation is microorganism adhesion or adherence to a surface of the implanted device, such as a catheter.
  • Negatively charged heparin molecules injected into the catheter lumen bind to the positively charged catheter surface, and heparin sulfate moieties are exposed on vascular endothelium lining catheter lumens.
  • Linear heparin binding motifs present on the surface of microorganisms, such as C. albicans interact either with heparin or with heparin sulfate and enable the organism to attach to the inside of the catheter.
  • patient cells can engraft on a device, providing a surface to which microbes may specifically attach.
  • HBM heparin binding motifs
  • biofilm formation It is extremely difficult to treat patients with infections arising from biofilms; antibiotics and host defenses cannot penetrate the biofilm and microorganisms enmeshed within the biofilm are thus shielded. Because microbe interaction with heparin or heparan sulfate initiates biofilm formation, a method to reduce or prevent biofilm formation is desirable.
  • the described purified antibody blocks binding and prevents biofilm formation.
  • the inventors have shown that interactions between heparin and surface proteins on microorganisms such as C. albicans facilitate biofilm formation, and subsequent infection of the bloodstream when biofilm projections break off into a catheter lumen and enter the bloodstream. To prevent or eliminate such biofilm formation, it is thus desirable to reduce or prevent such binding using the inventive method.
  • Examples of medical devices include, but are not limited to, catheters (e.g., venous, arterial, hemodialysis, peritoneal, urinary catheter, etc.), lines (e.g., central line), shunts (e.g., central nervous system shunt, dialysis shunt, etc.).
  • catheters e.g., venous, arterial, hemodialysis, peritoneal, urinary catheter, etc.
  • lines e.g., central line
  • shunts e.g., central nervous system shunt, dialysis shunt, etc.
  • the patient is administered, before, during, and/or after the device is implanted or installed, a pharmaceutically acceptable composition of a purified human antibody to a peptide HKQEKQKKHQIHKV (SEQ ID NO: 1), under conditions to reduce or prevent biofilm formation on the device.
  • the method has efficacy against biofilm formation by at least these microorganisms: Enterococcus
  • Staphylococcus aureus (S. aureus), Enterobacter cloacae (£. cloacae), or Acinetobacter baumannii (A. baumannii).
  • the Staphylococcus aureus with protein A removed (Spa S. aureus) is an artificially created laboratory strain and was used to show that binding of the described purified human antibody was not by the Fc receptor.
  • the patient is administered, before, during, and/or after the device is implanted or installed, a pharmaceutically acceptable composition of a purified human antibody to a peptide HKQEKQKKHQIHKV (SEQ ID NO: 1), under conditions to reduce or prevent biofilm formation on the device.
  • Microbial pathogens such as Candida albicans (C. albicans) colonize indwelling catheters due to their propensity to form biofilms in implanted medical devices.
  • Other microbial pathogens such as Enterococcus faecalis (£. faecalis), Staphylococcus aureus (S. aureus), Enterobacter cloacae (£. cloacae), and Acinetobacter baumannii (A. baumannii) also cause infections of medical devices and indwelling catheters.
  • the method has efficacy against biofilm formation in vitro by at least these microorganisms: Candida albicans (C. albicans, Enterococcus faecalis (£. faecalis), Staphylococcus aureus (S.
  • the human antibody is affinity purified by contacting a composition comprising the human antibody, e.g., GAMMAGARD®, with a stationary phase containing a solid support and the peptide
  • HKQEKQKKHQIHKV SEQ ID NO: 1 as the affinity ligand, washing the stationary phase with a wash buffer, and eluting the human antibody from the stationary phase by contacting an elution buffer with the stationary phase.
  • Human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1) was purified from a commercial preparation GAMMAGARD® and recognized, and bound to, peptide
  • GAMMAGARD® is a derivative of human plasma used to treat patients with primary immunodeficiencies. The components of GAMMAGARD® that did not bind the stationary phase of an affinity column, i.e. the flow through, did not bind to the peptide. Human antibody to peptide
  • HKQEKQKKHQIHKV (SEQ ID NO: 1) binds to not only Candida spp. but also to each of E. faecalis, S. aureus, Spa S. aureus, E. cloacae, and A. baumannii.
  • the solid support may be, e.g., agarose beads, sepharose, polyacrylamide, vinyl polymers, silica, etc.
  • the wash buffer may be, e.g., phosphate-buffered saline (PBS), Tris-buffered saline, or other isotonic buffers.
  • the elution buffer may be, e.g., glycine (e.g., 0.1 M glycine at pH 2.5-2.8); 50 mM Triethanolamine, pH 1 1 .5; 0.1 % Triton X-100 may be included with either elution buffer (high or low pH).
  • Buffers containing high concentrations of divalent cation have been used in other systems, as well as methods specific to the particular antigen (e.g. peptides, sugars).
  • the buffer exchange step may be dialysis against PBS or other isotonic buffer under cold room conditions (e.g., 4°C) or diafiltration., or as known in the art.
  • the following is an exemplary purification method for the antibody to peptide
  • HKQEKQKKHQIHKV (SEQ ID NO: 1). Equilibrate an agarose-peptide column (1 ml agarose) to room temperature. Equilibrate the column with 10 column volumes PBS. Dilute 0.5 ml of the
  • immunoglobulin-containing composition with an equal volume of PBS; this volume would of course depend on the efficiency of the column, the starting material, etc.
  • Add the diluted sample to column allow sample to enter resin bed, and incubate on a laboratory shaker for two hours, or recirculate over the resin using a peristaltic pump. Collect the unbound fraction (flow through). Wash with 8 x 1 ml PBS, collecting 1 ml fractions. Elute bound antibody with 8 x 1 ml 0.1 M glycine pH 2.5 into tubes containing 100 ⁇ 1 1 M Tris pH 8.0. Measure protein content (e.g., using a NANODROPTM UV spectrophotometer) in each fraction and combine fractions containing > 0.1 mg/ml protein. Dialyze the eluted antibody against cold PBS overnight in cold room. Recover the dialyzed antibody and measure the final antibody concentration after dialysis. Store at -80°C. The column is extensively washed with PBS and stored for repeated use.
  • GAMMAGARD® Boxter LE1500190
  • PBS pH 7.4 Maniatis formulation
  • Sulfolink coupling kit Pieris/Thermo, Rockford IL 44999
  • custom peptide Genscript, Piscatawy NJ
  • Fab Preparation kit
  • the purification procedure can be scaled up, particularly with the use of a larger volume of resin, a peristaltic pump to recirculate antibody in step 4 and a continuously monitoring fraction collection apparatus for steps 6-8.
  • Dialysis can also be performed with pressure driven membranes or with calibrated desalting columns.
  • the exemplary ELISA procedure is performed as follows. Peptide C-HKQEKQKKHQIHKV is suspended at a concentration of 10 ⁇ 9 ⁇ in 50 mM sodium carbonate buffer pH9.5. Peptide (100 ⁇ ) is added to wells of a 96 well Nunc Maxisorp (ThermoFisher, Waltham, MA) immunoassay plate and incubated at room temperature for 24 hours in a humid chamber.
  • Excess antigen is removed and the wells washed twice with 200 ⁇ distilled water. Each well surface is blocked with 200 ⁇ of 1 % solution of bovine serum albumin (BSA) in isotonic buffer, e.g. PBS, for an hour at 37°C in a humid chamber. Excess blocking buffer is removed and the wells rinsed twice with distilled water. Serum dilutions are prepared in binding buffer consisting of 1 % BSA and 0.1 % Tween® 20 in PBS. Dilutions (100 ⁇ ) of serum are added to wells and incubated for an hour at 37°C in a humid chamber. Buffer only controls are included. Serum is removed and wells washed twice with distilled water.
  • BSA bovine serum albumin
  • Secondary antibody (donkey anti-human IgG conjugated to horseradish peroxidase, Jackson ImmunoResearch Labs) is diluted in binding buffer, 100 ⁇ added to each well, and incubated for an hour at 37°C in a humid chamber. The conjugate is removed and wells washed three times with PBS/0.1 % TWEEN® 20, and twice with distilled water. 3,3',5,5'-tetramethylbenzidine soluble substrate (SureBlue Reserve, KPL/SeraCare) (100 ⁇ ) is added to each well and developed at room temperature. The reaction is stopped with 100 ⁇ 1 M HCI and the assay read at 450 nm.
  • the purified human antibody exhibited strong binding of the antibody to peptide
  • HKQEKQKKHQIHKV (SEQ ID NO: 1 ) at dilutions ranging from 1 :500 to 1 :2500 in an ELISA. Titration data are shown in FIG. 1 .
  • An exemplary binding assay was performed as follows: C. albicans was grown in minimal medium to log phase, washed, and fixed in 2% formaldehyde. An aliquot containing 5x10 5 organisms was incubated with affinity purified human or rabbit (200 ⁇ g/ml) antibody followed by the relevant anti- IgG Alexafluor 647 conjugated secondary antibody and flow cytometric analysis. Affinity purified human antibody recognized an epitope on C. albicans, as did affinity purified rabbit antibody.
  • FIG. 2 compares data from flow cytometry analysis using no primary antibody, with data obtained using the affinity purified human antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1).
  • FIG. 3 compares data from flow cytometry analysis using no primary antibody with data obtained using the affinity purified rabbit antibody to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1). Data from FIGS. 2-3 are tabulated below:
  • the human antibody binds to C. albicans about 20 fold more strongly than the rabbit antibody that prevented biofilm formation in vitro and in vivo, reported in Green et al., J. Infectious Diseases 208 (2013)1695-1704, which is expressly incorporated by reference herein in its entirety.
  • the affinity purified human antibody binds to other species of Candida, measured by flow cytometry, as shown below.
  • the following table demonstrates data for antibody binding to peptide HKQEKQKKHQIHKV (SEQ ID NO: 1) to selected prokaryotic microorganisms, as measured by flow cytometry.
  • HKQEKQKKHQIHKV SEQ ID NO: 1 occurred in this order: greatest binding to E. faecalis > S.
  • aureus Spa S. aureus > E. cloacae > A. baumannii. Even with the relatively low binding to A.
  • Immunoglobulins bind antigen via the N-terminal, variable regions of the heavy and light chains of the quaternary protein structure (VH and VL), termed Fab.
  • VH and VL variable regions of the heavy and light chains of the quaternary protein structure
  • immunoglobulins is responsible for secondary in vivo activities of immunoglobulins, such as activation of the complement cascade and interactions with cells of the immune system. Some of these secondary activities are beneficial when IVIG (GAMMAGARD) is used to correct immune deficiencies, but may not be helpful in the context of blocking biofilm formation.
  • IVIG GAMMAGARD
  • Fc also binds directly to S. aureus via protein A on the surface of the bacteria, in a manner that hinders immune recognition.
  • IgG can be digested with papain under controlled conditions to produce single chain Fab.
  • Fab preparation kit Pierce/Thermo cat # 44985
  • techniques for producing single chain Fab fragments are known in the art. Briefly, papain bound to a support resin is activated with digestion buffer
  • Affinity purified human anti-peptide antibody is equilibrated into digestion buffer using e.g. a desalting column.
  • the antibody is mixed with the papain resin at 37° for several hours, depending on the amount of protein, and digested material is eluted from the column matrix with PBS.
  • This eluate will contain Fab, Fc, and undigested IgG.
  • the eluate is then applied to a (recombinant) protein A column.
  • Protein A is an S. aureus protein which avidly binds the Fc portion of immunoglobulin molecules.
  • the Fab components pass through the matrix without binding; cleaved Fc and intact IgG are bound to the matrix.
  • the Fab containing fractions are combined and concentrated as needed.
  • the Fab-containing fraction is assayed for completeness of digestion and purity by SDS-PAGE.
  • Papain bound to a support resin is activated with digestion buffer.
  • Purified anti-KKHQ antibody is equilibrated into digestion buffer using a desalting column.
  • the antibody is mixed with the papain resin at 37° for several hours, depending on the amount of starting material.
  • the digested material is eluted from the column matrix by centrifugation and PBS washes. This eluate contains Fab, Fc, and undigested IgG.
  • Protein A is an S. aureus protein which avidly binds the Fc portion of immunoglobulin molecules.
  • the Fab components pass through the matrix without binding. Cleaved Fc and intact IgG components are bound to the matrix.
  • the Fab containing fractions are combined and concentrated as needed.
  • the Fab-containing fraction is checked for completeness of digestion and "purity" by SDS-PAGE.
  • This procedure may be scaled up as above, replacing the centrifugation steps specified in the manufacturer's protocol with a closed, pump-driven system.
  • IgG is cleaved by the enzyme papain to produce two Fab fragments per molecule of IgG. Each Fab fragment still binds to the antigen epitope, but will not crosslink.
  • the inventive treatment separates the very specific binding and blocking activity of the antibody from the functions of the Fc portion of IgG, which preclude immune activation and counterproductive binding to certain microorganisms (e.g. Staphylococcus aureus).
  • the Fab fragment is used in the method.
  • an Fab fragment of the affinity purified human antibody is provided.
  • affinity purified anti-peptide whole antibody or Fab derived from the affinity purified antibody was assayed for C. albicans as described above, using 200 ⁇ g protein (not corrected for the difference in structure or molecular weight).
  • the Fab portion of affinity purified human anti-peptide antibody bound C. albicans to the same extent as the whole antibody, as shown by the percent positive. Differences in mean and median fluorescence intensity cannot be compared directly due to limitations of the method, i.e. secondary antibody to the whole immunoglobulin molecule, Heavy+Light chains were used.
  • binding capacity of affinity purified anti-peptide whole antibody or Fab derived from the affinity purified antibody was assayed as described above, using 200 ⁇ g protein (not corrected for the difference in structure or molecular weight) against several different strains of S. aureus. Binding to the Spa-strain (derived from Newman, Corrigan et al., Surface proteins that promote adherence of Staphylococcus aureus to human desquamated nasal epithelial cells. BMC Microbiology 2009
  • Applicant incorporates by reference the material contained in the accompanying computer readable Sequence Listing identified as 070248_108_ST25.txt, having a file creation date of May 31 , 2018, 7:49 a.m., and file size of 459 bytes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps humain purifié dirigé contre le peptide HKQEKQKKHQIHKV (SEQ ID No: 1) et son procédé de purification. Des procédés et des réactifs pour améliorer ou prévenir la formation d'un biofilm sur la surface d'un dispositif à demeure ou implanté chez un patient qui induit une perte de virulence des micro-organismes appartenant à l'espèce Candida et/ou à l'espèce Staphylococcus par administration de l'anticorps humain purifié dirigé contre le peptide HKQEKQKKHQIHKV (SEQ ID No: 1) sont en outre décrits.
PCT/US2018/035278 2017-06-08 2018-05-31 Anticorps humain purifié se liant au motif microbien de liaison à l'héparine et son procédé d'utilisation WO2018226493A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516823P 2017-06-08 2017-06-08
US62/516,823 2017-06-08

Publications (1)

Publication Number Publication Date
WO2018226493A1 true WO2018226493A1 (fr) 2018-12-13

Family

ID=64566187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/035278 WO2018226493A1 (fr) 2017-06-08 2018-05-31 Anticorps humain purifié se liant au motif microbien de liaison à l'héparine et son procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2018226493A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232733A1 (en) * 2005-04-13 2009-09-17 O'nuallain Brian Diagnostic and Therapeutic Potential of Immune Globulin Intravenous (IGIV) Products
US20150050284A1 (en) * 2012-04-20 2015-02-19 Children's Hospital Medical Center Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232733A1 (en) * 2005-04-13 2009-09-17 O'nuallain Brian Diagnostic and Therapeutic Potential of Immune Globulin Intravenous (IGIV) Products
US20150050284A1 (en) * 2012-04-20 2015-02-19 Children's Hospital Medical Center Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices

Similar Documents

Publication Publication Date Title
US11780909B2 (en) Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM
RU2644240C2 (ru) Композиции, содержащие секреторноподобные иммуноглобулины
Kuo et al. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease
US7754217B2 (en) HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US20200048331A1 (en) Immunoregulatory structures from normally occuring proteins
KR20110017383A (ko) 황색 포도상구균-특이적 항체 제제
CN104245728A (zh) 用于富集iga的方法
Muronetz et al. Isolation of antigens and antibodies by affinity chromatography
US9920113B2 (en) Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
WO2018226493A1 (fr) Anticorps humain purifié se liant au motif microbien de liaison à l'héparine et son procédé d'utilisation
US5807982A (en) Affinity purified heparin
JPH02299583A (ja) トロンビン阻害因子に特異的なモノクローナル抗体
US20200190166A1 (en) Polyvalent immunotherapeutics of high specificty based on modified antibodies and a lyophilized injectable formulation highly safe and effective
KR100245542B1 (ko) 응고 인자 xiii 또는 xiiia의 정제방법 및 인자 xiiia에 대한 모노클로날 항체
US20140124448A1 (en) IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES
WO2024027771A1 (fr) Protéine de fusion d'anticorps ciblant fap et tgfβ, et son utilisation
JP2010155822A (ja) ルイスｙ抗原に関連した疾患の予防または治療用の医薬組成物、ならびにルイスｙ抗原検出用のキット
JPH05503842A (ja) モノクローナル抗体、ハイブリドーマおよびそれらの用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18812614

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18812614

Country of ref document: EP

Kind code of ref document: A1